Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host.

Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, Durack DT, Levin MJ, Segreti AC, Balfour HH Jr.

Am J Med. 1982 Jul 20;73(1A):229-35. doi: 10.1016/0002-9343(82)90097-3.

Intravenous acyclovir was evaluated in the treatment of 97 immunocompromised patients with mucocutaneous herpes simplex virus infection in a randomized, double-blind, placebo-controlled trial. Acyclovir recipients had significantly shorter periods of virus shedding (p less than 0.0002) and lesion pain (p less than 0.01), and more rapid lesion scabbing (p less than 0.004) and lesion healing (p less than 0.04). The most common adverse reaction was a low incidence of peripheral vein irritation; no serious toxicity could be definitely attributed to acyclovir treatment even in these seriously ill patients. Intravenous acyclovir offers both safe and effective treatment for mucocutaneous herpes simplex virus infection in the immunocompromised host.

PMID: 7048914

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.